Home Newsfeeds Guggenheim Downgrades Shoals Technologies Gr to Neutral

Guggenheim Downgrades Shoals Technologies Gr to Neutral

Guggenheim analyst Joseph Osha downgrades Shoals Technologies Gr (NASDAQ:SHLS) from Buy to Neutral.

byBenzinga Newsdesk

September 9, 2022

1 minute read

Guggenheim analyst Joseph Osha downgrades Shoals Technologies Gr (NASDAQ:SHLS) from Buy to Neutral.

Analyst Ratings

Analyst Expectations for Designer Brands’s Future

By Benzinga Insights

June 6, 3:02 PM

Analysts have provided the following ratings for Designer Brands (NYSE:DBI) within the last quarter: Bullish Somewhat Bullish Indifferent…

DBI

SEC Rejects Coinbase’s Rulemaking Petition, Insists Current Laws Are Applicable

By Murtuza Merchant

December 15, 1:24 PM

U.S. regulators rejected a rulemaking petition submitted by Coinbase Global Inc. (NASDAQ: COIN). What Happened: Last year, Coinbase drafted a “petition for rule making."

COIN

Portland General Electric Faces Pressure in ’23 Before A Brighter ’24, Analyst Says

By Shivani Kumaresan

January 23, 2:58 PM

Credit Suisse analyst Nicholas Campanella reiterated a Neutral rating on the shares of Portland General Electric Company (NYSE:POR) and raised the price…

POR

TriSalus Life Sciences Announces Late Breaker And Additional Data Presentations On Liver Metastases And Pancreatic Cancer At The Society For Immunotherapy Of Cancer 2023 Annual Meeting

By Benzinga Newsdesk

October 25, 9:09 AM

TriSalus Life Sciences® Inc., (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced it

TLSI

Guggenheim Downgrades Shoals Technologies Gr to Neutral

Related Posts

Analyst Expectations for Designer Brands’s Future

SEC Rejects Coinbase’s Rulemaking Petition, Insists Current Laws Are Applicable

Portland General Electric Faces Pressure in ’23 Before A Brighter ’24, Analyst Says

TriSalus Life Sciences Announces Late Breaker And Additional Data Presentations On Liver Metastases And Pancreatic Cancer At The Society For Immunotherapy Of Cancer 2023 Annual Meeting